key: cord-0927864-bmok0jqa
authors: A Abdullah, Ashwaq; Abdullah, Rasedee; A Nazariah, Zeenathul; N Balakrishnan, Krishnan; Firdaus J Abdullah, Faez; A Bala, Jamilu; Mohd-Lila, Mohd-Azmi
title: Cyclophilin A as a target in the treatment of cytomegalovirus infections
date: 2018-11-18
journal: Antivir Chem Chemother
DOI: 10.1177/2040206618811413
sha: 5fc9523915b057c03afa54f111fe9fd1995dd1ad
doc_id: 927864
cord_uid: bmok0jqa

BACKGROUND: Viruses are obligate parasites that depend on the cellular machinery of the host to regenerate and manufacture their proteins. Most antiviral drugs on the market today target viral proteins. However, the more recent strategies involve targeting the host cell proteins or pathways that mediate viral replication. This new approach would be effective for most viruses while minimizing drug resistance and toxicity. METHODS: Cytomegalovirus replication, latency, and immune response are mediated by the intermediate early protein 2, the main protein that determines the effectiveness of drugs in cytomegalovirus inhibition. This review explains how intermediate early protein 2 can modify the action of cyclosporin A, an immunosuppressive, and antiviral drug. It also links all the pathways mediated by cyclosporin A, cytomegalovirus replication, and its encoded proteins. RESULTS: Intermediate early protein 2 can influence the cellular cyclophilin A pathway, affecting cyclosporin A as a mediator of viral replication or anti-cytomegalovirus drug. CONCLUSION: Cyclosporin A has a dual function in cytomegalovirus pathogenesis. It has the immunosuppressive effect that establishes virus replication through the inhibition of T-cell function. It also has an anti-cytomegalovirus effect mediated by intermediate early protein 2. Both of these functions involve cyclophilin A pathway.

Viruses, without their own replication machinery, depend on the host cell to proliferate. The viruses interact with host cells, activates enzymes and co-factors required for their replication. The response of the host cell thus reflects the pathogenic properties of the virus. 1, 2 In the treatment of viral diseases, the drugs primarily target special viral proteins. Current antiviral drugs include nucleotide analogs, [3] [4] [5] [6] [7] neuraminidase enzyme and M2 channel, 8, 9 reverse transcriptase and protease inhibitors, 10, 11 and chemokine receptor 5 (CCR5) antagonist. 12 Many drugs targeting viral proteins are fraught with cytotoxicity and tend to cause drug resistance. 13 Although drugs that target cellular factors or pathways have the advantage of overcoming cellular barriers, their toxicities compromise their usefulness. [14] [15] [16] [17] For this reason, there is a need to discover alternative antiviral compounds with minimal side effects. 18 Immunosuppressed patients undergoing organ transplantation are susceptible to cytomegalovirus (CMV) infections that could cause rejections. [19] [20] [21] Interestingly, two immunosuppressive drugs, mycophenolic acid and mizoribine, 22 have better anti-CMV activities than ganciclovir [23] [24] [25] [26] [27] and allow for good graft survival. [28] [29] [30] Some immunosuppressive drugs were developed to target specific protein kinases essential for virus replication. Among these are artesunate, a drug that inhibits cellular kinase signalling, NF-jB, and Sp1 proteins, 31, 32 and sirolimus and everolimus, rapamycin inhibitors targeting cellular signals. [33] [34] [35] [36] [37] These drugs were shown to be active against ganciclovir-and foscarnet-resistant CMV strains. 38, 39 This review discusses the association between cellular pathways mediated by CMV and cyclosporin A (CsA) and demonstrates that CsA can be used both as an immunosuppressive drug in organ transplantation and as an anti-CMV agent.

CMV is a DNA virus of the herpesviridae family. 40 The highly species-specific human cytomegalovirus (HCMV) cannot be studied in animals. This results in the development of many animal models for the virus. [41] [42] [43] [44] [45] [46] Seroprevalence studies have shown that 30-97% of the population is seropositive for CMV. [47] [48] [49] The immune system can easily control the virus from causing active infection and facilitating lifelong latency. 50, 51 Immunosuppressed transplant recipients, HIV patients, and the foetus are at risk of acquiring CMV infections. [52] [53] [54] [55] [56] [57] [58] The high risk of infection in solid organ transplantation (SOT) recipients is associated with serostatus of the donor and recipient, type of transplanted organ, host immune status, and viral factors. In organ and tissue transplantation, CMV infections were mostly reported in the seropositive (Dþ)/ CMV-seronegative (R-) recipients rather than in D-/R-recipients. 57, 59, 60 It was also shown in hematopoietic cell transplant, the greatest risk of infection is when the donor is CMV seronegative (D-) and the recipient seropositive (Rþ). 61 In pregnant women, among factors that increase the risk of CMV infections are socioeconomic status, parasitic infections, CMV viral load and serostatus, age, non-Caucasian, education level, and close contact with young children, the prevalence of CMV infection is between 50 and 97%. [62] [63] [64] [65] [66] Between 5 and 10% of babies born of mothers with primary CMV infection show neurological diseases at birth, making the prevalence of CMV-related disabilities higher than other childhood diseases. 57, [67] [68] [69] The risk of vertical transmission of CMV is higher in primary (33%) than that in non-primary CMV infection (1%), 70 but in both infections, symptomatic congenital CMV infections may also develop. 71-75 Primary infection occurs in most seropositive women and in 1 to 4% of seronegative women. In the USA, 77% of congenital infections are acquired from non-primary CMV infection and only 22% from primary infections. [76] [77] [78] Thus, 77% of congenital infection is acquired from non-primary CMV infection compared to 22% of primary infection in USA. 78 Regarding CMV disease outcomes, there is no evidence that the symptomatic outcomes in both primary and non-primary CMV infections are different. 71, 73, 79 The greatest risk of CMV infection is during the period of fetal organogenesis, that is in the first and early second trimesters. Vertical transmissions mostly occur in the third trimester, and fetuses are mostly born healthy. There seems to be no difference in symptoms among babies born of pregnancies affected with primary and non-primary CMV infections. 80 Mortality is between 20 and 30% in symptomatic congenitally infected children, 81, 82 resulting from liver dysfunction, coagulation disorders, and secondary bacterial infections. 82 Complications of CMV congenital infections include central nerve system (CNS) diseases, such as meningoencephalitis, calcification, microcephaly, disruption of neuronal migration, germinal matrix cysts, ventriculomegaly, cellular hyperplasia, lethargy, hypotonia, seizure, and chorioretinitis. 83, 84 Complications are more severe if CMV infections occur at the early stage of pregnancy. 85 In some newborns, post-natal CMV infections cause hepatitis, neutropenia, thrombocytopenia, and premature and low birth weight. 86 Sensorineural hearing loss (SNHL) due to virus replication in the inner ear was reported in 15 to 25% of young kids. [87] [88] [89] This disorder can develop early at birth (in 5.2% of symptomatic or asymptomatic neonates) or later in childhood (in 15.4% of children). 52, 87, 88, 90 In approximately 50% of infants, the congenital infection may manifest as the more severe and symptomatic cytomegalic inclusion disease (CID) or cytomegalic inclusion body disease (CIBD). 67, 68, 91, 92 Infants with CID can develop other CMV neurological diseases. 84, [93] [94] [95] [96] [97] CMV can reach the brain of foetuses. Brain CMV infections are associated with viral replication in the endothelial cells of the blood-brain barrier (BBB), 98 a process that facilitates virus-crossing of the brain parenchyma and access to astrocytes. [99] [100] [101] [102] Another way the virus enters the brain is by infecting the ependymal cells of choroids plexus, leading to dissemination of virus in the cerebrospinal fluid and subsequently infecting the brain parenchyma. 103 The virus can establish latent infections in myeloid cells that eventually infiltrate the brain and develop into microglia cells. 103 Destruction or injury to BBB endothelial cells can result in extravasation of monocytes and facilitate brain infection. 104 In the nervous tissues, CMV induces injuries by interfering with cell differentiation, morphogenesis and survival, controlling apoptosis mechanism, infecting neural stem cell and interfering with brain developmental process, and impacting the CMV replication on the endovascular system. 89 Viral replication interferes with brain development during migration of neocortical neurons to the cortical plate, causing disabilities. [105] [106] [107] [108] Cyclophilin A Cyclophilins (CyPs) are a group of highly conserved cellular proteins, [109] [110] [111] [112] found ubiquitously in animal and plant tissues. These proteins have unique chemical structures consisting of 109 amino acids with. These amino acids contain variations in the interaction domain among proteins from various locations and of different functions. 113 At least 16 CyPs have been identified. 114 Although they differ in distribution in tissue and organ localization, their structures are similar to the same peptidyl-prolyl isomerase (PPIase) activities. 115 In humans, seven CyPs (40 kDa) have been identified, which are hCyPA, hCyPB, hCyPC, hCyPD, hCyPE, hCyP40, and hCyPNK. 110, 116 The cellular functions of CyPs have been observed in protein folding and trafficking. 117, 118 Cyclophilin A (CyPA), which can bind cyclosporin A (CsA), was first isolated from bovine thymocytes. 115, 119 CyPA resembles the high abundance CyPs in eukaryotic cells 119 with concentration ranging from 0.1 to 0.6% of total cellular proteins. 111 CyPA is encoded by Cyp18 gene in chromosome 7p11.2-p13 and consists of 165 amino acid with a molecular weight of 18 Â 10 3 Daltons. 120 In humans, CyPA is composed of eight antiparallel b-barrel structure enclosed by two a-helices at each location. The hydrophobic core of CyPA contains one hydrophobic and seven aromatic residues within the drum of the molecule or the CsA-binding area. The CsA-binding site is composed of a loop region at Lys118 to His126 and four b-strands at B3 to B6 position. 111, 120 CyPA plays an important role in various cellular functions, including inflammation and apoptosis. [121] [122] [123] [124] [125] [126] [127] [128] [129] This protein can stimulate the immune response and is produced by inflammatory cells such as endothelial cells, monocytes, vascular smooth muscle cells, and platelets. [130] [131] [132] Extracellular CyPA, through interaction with cell membrane heparin receptor and CD147, also functions as a chemoattractant for monocytes, neutrophils, eosinophils, and T lymphocytes. 133 Like other CyPs, CyPA acts as a chaperone in the regulation of cellular protein 111, 120, 125 and receptor expression and activities. [134] [135] [136] This protein is also involved in several signalling pathways, such as the signal transduction pathway unique to T lymphocytes and the T cellspecific interleukin-2 tyrosine kinase (Itk). [137] [138] [139] In the brain, CyPA is mostly localized in the neurons, 140, 141 where it plays a role in neuronal differentiation, embryo growth, and adult cortical plasticity. 142, 143 CyPA maintains the integrity and function of BBB and protects neurons during traumatic brain injury by blocking BBB permeability and the effects of ischemia and oxidative stress. [144] [145] [146] In brain injuries, CyPA induces endothelial cell proliferation and migration as well as recruiting monocytes for the repair of brain blood vessels. 135 Moreover, CyPA induces extracellular signal-regulated kinases (ERK) and protein kinase B (PKB) or Akt signalling by binding to the cell surface receptor, CD147. This binding stimulates the expression of the anti-apoptotic protein Bcl-2 147, 148 and mediates neurogenesis in brain protection and repair. 133, 144 Cyclosporin A Cyclosporin A (CsA), an 11-amino acid cyclic peptide (Figure 1 ), can be extracted from the fungus, Tolypocladium inflatum Gams. 149 It is an immunosuppressive drug primarily used for organ transplantation. [150] [151] [152] This drug is also used for the treatment of renal, neurodegenerative, and autoimmune diseases 153, 154 and has been recommended for the treatment of rheumatoid arthritis, psoriasis, atopic dermatitis, and endogenous uveitis. [155] [156] [157] [158] The immunosuppressive activity of CsA is the result of the formation of CsA-CyPA complex that has a high affinity for calcineurin, a cellular phosphatase mediating T-cell activation. 120, [159] [160] [161] The CsA-CyPA complex is located at the interface of calcineurin, between the catalytic and regulatory subunits, and controls phosphatase activity and biological functions. 159, 162, 163 CsA also affects the expression of AP-1 and NF-jB, [164] [165] [166] modulates the antigenspecific immune and Ca 2þ -independent responses, 167 and blocks the JNK and p38 MAPK signalling pathways. 161, [168] [169] [170] However, the use of CsA in the treatment of diseases has adverse effects. It causes abnormal glomerular filtration, nephrotoxicity, neurotoxicity, hepatoxicity, and cardiovascular disorders 171, 172 through calcineurin and other factors including endothelin and TGF-b1. 173 CsA, through T cells, can induce inflammation and apoptosis. This is mediated by JNK and p38 MAPK, the activators of T cell receptors, 161 ERK, and the transcription factor AP-1. 174 AP-1 controls cellular processes including differentiation, proliferation, and apoptosis. The activation of JNK and p38 MAPK also requires the involvement of the CsAsensitive protein kinases, MKK6 and MKK7. 161 The majority of mitogen-activated protein kinases (MAPK), MAPK kinase (MAPKK), and MAPKK kinase (MAPKK-K) 175-180 require MEKK1 to activate MKK7. MEKK1 mediates JNK pathway that modulates NF-jB activity, 181 JNK pathway signals, and NF-jB activity under CsA control. [182] [183] [184] CsA mediates JNK signalling pathway through Rac1, a member of the Rho subfamily of small G-proteins, especially through its guanine nucleotide exchange factor (Vav1). Vav1 controls IL-2 expression. [185] [186] [187] Other immunosuppressive agents such as FK506 and tacrolimus (calcineurin NFAT pathway inhibitor), use the same mechanism to block JNK and p38 pathways, and subsequently T-cell activation. Similarly, the immunosuppressive activity of CsA mediated by calcineurin blocks JNK and p38 activation. [188] [189] [190] Unlike these immunosuppressive agents, calcineurin controls JNK while in complex with PKC-u. [191] [192] [193] CsA derivatives

There are several CsA derivatives ( Figure 2 ) that interact well with viruses and do not cause serious side effects. [194] [195] [196] Among these derivatives, alisporivir (Debio-025) (Figure 2(a) ), a non-immunosuppressive analog of CsA, was synthesized to contain sarcosine instead of d-methylalanine at position 3 of the PPIase domain and methyl-leucine instead of ethylvaline at position 4 of the calcineurin domain. These modifications have altered the PPIase activity and calcineurinbinding ability of the derivatives. 197 However, alisporivir still results in side effects including reversible hyperbilirubinemia and pancreatitis when used in combination with PEG-IFNa2a and ribavirin to treat hepatitis C virus (HCV) infection. 198 NIM811 ( Figure  2 (b)), another nonimmunosuppressive analog of CsA, is similar in structure to the parent molecule with one modification: methyl-leucine at position 4 being replaced by methyl-isoleucine. This derivative has antiviral effects 195 while exhibiting the same pharmacokinetic profile as CsA without nephrotoxicity. 196, 199 In 2010, SCY-635 ( Figure 2 (c)) was synthesized. 200 This CsA derivative inhibits HCV infection 201 without detectable inhibition of calcineurin phosphatase. Treatment with this drug is associated with transient increases in interferon a, k1, and k3, the cytokines responsible for the clearance of the viruses. 202 Another derivation of CsA, EDP-546, is metabolically stable with favorable pharmacokinetics that allows for less frequent and low therapeutic dosing of the drug. It is also an effective bilirubin transporter without affecting CYP450, a major protein in drug metabolism. 203, 204 Sanglifehrin A (SFA) (Figure 3 ) is a new immunosuppressive agent 205 isolated from the Streptomyces strain A92-308110. This protein interacts strongly with CyPA 206-208 but not with calcineurin phosphatase. 209 It is also a potent inhibitor of mitochondrial permeability transition and heart reperfusion injury. 210.

CyPA is an essential protein for the HCV and hepatitis B virus (HBV) replications. In HCV, CyPA interacts with several viral proteins including serine protease, NS3, viral RNA-dependent RNA polymerases, NS5A and NS5B, and cysteine protease, NS2. [211] [212] [213] [214] [215] The interactions between CyPA with NS5A and NS5B stimulate viral genome replication, 213,215-221 virion morphogenesis, 222-224 and viral particles assembly through the NS5A-D3 domain. 213, 222, 224, 225 The replication of viruses is also mediated by other proteins including eEF1A and T-cell intracellular antigen 1 (TIA-1). 226,227 eEF1A binds to the 3 0 -terminal stemloop of flavivirus genomes and facilitates the synthesis of minus-strand RNA. 226 CsA can block CyPA-NS5 interaction 213,228 and indirectly inhibit the genomic RNA amplification. 220, 225, 229 The inhibitory effect of CsA and its derivative on HBV is associated with the distribution of mitochondrial transition pore and calcium signalling. 230 CyPA that can form a complex with CsA is important for virus entry by triggering the expression of HBV surface antigen (HBsAg) and mediating virus DNA replication and envelope protein secretion. 231-237 The formation of the CsA-CyPA complex inhibits HCV and HBV through sodium taurocholate co-transporting polypeptide receptor. 230, 238 CyPA also mediates influenza virus replication through its association with the virus core. 239 In influenza viruses, CyPA interacts with M1 protein, resulting in the interference of virus nuclear translocation and preventing post-transcription of the viral genome. 240 Inhibition of influenza virus replication by CsA and its non-immunosuppressive derivatives involves both the CyPA-dependent and independent pathways. 241, 242 The CyPA-independent inhibition occurs through the RNA polymerase II. 243 The inhibition of virus replication can also be achieved with the nonimmunosuppressive analogs of CsA such as SCY-635. 125, 241 Human immunodeficiency virus (HIV) is an RNA virus that causes acquired immunodeficiency syndrome (AIDS). The viral capsid undergoes morphological changes in the target cell cytosol. 244 This is mediated by cell factors, 245, 246 such as TRIM5 247 which forms the TRIM5-CyPA fusion complex, and TRIMCyp that blocks virus replication at the post-entry step. 248 TRIMCyp interacts with the retrovirus capsids, causing capsid disassembly and inhibits virus infection. 247, [249] [250] [251] The HIV-1 CA protein on the capsid surface facilitates interaction with cellular CyPA during infection and controls virus replication. CyPA also interacts with HIV-1 Gag polyprotein that mediates virus fusion, entry, uncoating, 252-258 viral genome integration into host DNA, [259] [260] [261] and modulates the immune response. 262 CsA and its analogs, Debio-025 and NIM811, interact with CyPA. This disrupts CyPA-binding loop located at the N-terminal of HIV-1 CA protein [254] [255] [256] 263, 264 and inhibits HIV-1 infection in certain cell types. 253, 265, 266 In severe acute respiratory syndrome (SARS) virus, CyPA binds to the SARS-CoV N protein 267 and mediates viral RNA synthesis. [268] [269] [270] In most coronaviruses, CyPA also interacts with the non-structural viral protein 1 (Nsp1).

Cell signals and CMV. CMV cellular entry and replication involve several factors including epidermal growth factor receptor (EGFR), integrin b1 and b2, and platelet-derived growth factor receptor-a (PDGFRa). [271] [272] [273] Binding to these receptors initiates Ca þ2 homeostasis, activation of phospholipase C and A2, the release of arachidonic acid and its metabolites, diacylglycerol that activates protein kinase C, and inositol triphosphate inducing calcium influx. [274] [275] [276] [277] [278] [279] [280] The virus also binds to avb3 integrin, another receptor that mediates actin depolymerization, facilitating virus translocation to the nucleus, 281 and activating the Src pathway. The alteration in cytoskeleton arrangement is also associated with the activation of avb3 integrin and EGFR receptors that reduce the activity of RhoA GTPase. 281, 282 The virus activates the extracellular signal-regulated kinase (ERK) 1/2, also known as MAPK, through the ERK/MEK1/2 pathway. These interactions that occur through MKK3, MKK6, and MKK4 kinases are important for viral replication. [283] [284] [285] HCMV replication requires the NF-jB to activate the major immediate early promoter (MIEP), [286] [287] [288] which is responsible for the transcription of more than 150 genes in cells. The NF-jB specific promoter 1 protein (Sp1) can be activated by HCMV IE1-72 and IE2-86 either independently or synergistically. [289] [290] [291] MIEP has a special site for the cell transcription factor that either stimulates or represses transcription of NF-jB, CREB/ATF, AP1, 292 Ying Yang1 (YY1), and Ets-2 repressor factors (ERF). [293] [294] [295] [296] [297] [298] The repression of transcription occurs through factors including those involved in the post-translational modification of histones 299,300 and TNF. 301, 302 In HCMV-permissive cells, MIEP associates with acetylated histone H4. In peripheral blood monocytes, MIEP associates with heterochromatin protein 1 (HP1), a chromosomal protein implicated in gene silencing. [303] [304] [305] [306] The HCMV remains latent in monocytes that serve as carriers for the virus. Although the mechanism of reactivation of HCMV is still not known, it has been suggested that the host complex facilitates chromatin transcription (FACT) binds to MIEP. The inhibition of this complex inhibits virus activation. 307 HCMV alters the expression of cell cycle regulatory proteins, the cyclin-dependent kinases. 308, 309 The infected cells are arrested at the G1 phase 310,311 of the cell cycle, during which macromolecules needed for cell growth and virus replication are synthesized. Both HCMV IE1-72 and IE2-86 can transactivate p53 promoter and induce p53 accumulation. However, HCMV IE1-72 represses p53 transactivation activity. 312 The outcomes of these interactions include stimulation of DNA synthesis, cell cycle arrest, and inhibition of apoptosis. 312 The virus also responds to alterations in cell growth and activation of host genes by interacting with histone deacetylases (HDACs) and retinoblastoma (Rb) tumor suppressor proteins via the LxCxEdependent pathway. [313] [314] [315] The binding of Rb protein to the E2F transcription factor partially controls cell growth in the HCMV-infected cells and other pocket proteins, such as p107. Cell growth arrest occurs when Rb protein represses the transcriptional activity of E2F transcription factors. 316, 317 The binding of E2F transcription factor to p107 causes the release and activation of E/CDK 2 kinases, 318,319 allowing for the cell cycle progression from G 1 to S phase.

HCMV increases the expression of tumor suppressor factor p53 in infected cell. 312, 320, 321 Both HCMV IE1-72 and IE2-86 bind to p53, although only HCMV IE2-86 can block its function. 312, 322, 323 HCMV can inhibit the apoptosis pathways through several strategies. Both HCMV IE1-72 and IE2-86 stimulate the anti-apoptotic PI3-K/Akt signalling pathway and delay the onset of p53 activity. 324, 325 Also, the CMV genes, UL36, a viral inhibitor of caspase-8induced apoptosis (vICA) and the UL37 gene encoding viral mitochondria-localized inhibitors of apoptosis (vMIA) affect permeabilization of the mitochondrial outer membrane, preventing the release of cytochrome c necessary for the activation of the pro-apoptotic caspase-3 pathway. 326 The adaptation and survival of the virus in host cells are further enhanced by its major tegument protein, pp150 protein. This protein binds to cyclin A2, causing cyclin A2-dependent phosphorylation and avoids the CDK-mediated inhibition of viral replication. 311, [327] [328] [329] CMV contains the UL146 and UL147 genes encoding for the CXC chemokines, vCXCL1 and vCXCL2. The virus uses these cytokines to activate CXCR1 and CXCR2, and preferentially attract neutrophils that can serve as virus carriers. 330, 331 The virus also possesses the UL 76 gene, which is an inducer of IL8 expression. 332 HCMV genome contains the G-proteincoupled receptors (GPCRs), UL33, UL78, US27, and US28. [333] [334] [335] [336] The GPCRs prevents leukocytes from recognizing HCMV-infected cells and blocks the effect of leukocytes on neighbouring cells. 335,337-340 US28, the best characterized among the GPCRs, stimulates migration of HCMV-infected cell to vascular injury sites leading to atherosclerosis and restenosis. 336, 341 Host cells infected with HCMV express type 1 interferons (IFNs), IFN-stimulated genes, and proinflammatory cytokines, 342 which are components of the innate cellular response that require the transcriptional activity of interferon regulatory factor 3 (IRF-3). 343 As a defence mechanism, the HCMV inhibits production of IFN by blocking the IFNa-stimulated responses and disrupting the IFNa signal transduction pathway, decreasing the expression of JAK1 and p48 [344] [345] [346] or the multiple IFN-responsive genes. 347-349 HCMV, particularly at late infection stage, also inhibits NF-jB signaling responsible for the production of proinflammatory cytokines, IL-6, CCL5, and TNFa. 350, 351 Cyclosporin A, CyPA, and CMV. CsA is an immunosuppressive agent 22,352 that can potentiate CMV infection. 103, [353] [354] [355] The immunosuppressive activity of CsA is via CsA-CyPA interaction with calcineurin. 159, 160 Most of the cellular pathways mediated by CyPA are sensitive to CsA. [356] [357] [358] These cellular pathways are fully controlled by CMV during viral infection and replication. 287, 288, 291, 292, 359 Additionally, they share signals such as NF-jB, MAPK such as MKK7 and MKK6, ERK1/2, P53, and JNK. The involvement of CyPA in the activation and replication of CMV 360 was demonstrated in the mouse model through the silencing of the CyPA mRNA. In fact, CyPA is required for HCMV lytic infection, latency establishment, and reactivation. 361 It also regulates IE protein and lytic genes expressions in HCMV replication cycle. The utilization of CyPA by CMV342 may deplete its concentration in organs and compromise cellular protein folding, differentiation, and functions. 361 If the nervous tissues are affected, the infection may cause CNS-associated abnormalities. These phenomena suggest that CyPA could be a potential therapeutic target in the treatment of HCMV infection. Although CsA is a common immunosuppressive drug used during organ transplantations and mediates HCMV reactivation in vivo (CsA-CyPA complex), this response may result from overall immunosuppression. 353 When CMV enters the cell, it stimulates the secretion of type I IFN as well as proinflammatory cytokines such as CyPA 362-364 through both NFjB and IRF3 transcriptions. 365 This is critical in CMV treatment. 366, 367 Both responses are controlled by CMV IE86 protein. 368 The other immune response to CMV is carried out by Toll-like receptor-2 (TLR2) stimulated by glycoproteins 364 and CD147. 369 Evidence from previous studies suggests 133,370 that CD147 operates as a legend for CyPA. 362 CD147 upregulates through CMV infection and is involved in inflammation similar to CMV. 371, 372 The interaction was established between CMV and ectodomain of CD147. 373 When CMV enters the cell, it stimulates CyPA production that interacts with CD147 to mediate virus replication and early immune response such as ISG15 gene, IFNB1 signalling to block CMV reinfection. 374 Additionally, the CD147-CyPA activates NFjB through ERK1/2 pathway which is important for both monocytes and macrophages. Modulation of the cellular microenvironment is necessary and was approved for CMV IL-10 previously. 375 CMV successfully downregulates CD147 by encoding MiR-U25-1-5p encoded by US 24-US26. 374 This microRNA is necessary for cellular modulation. It downregulates the CD147 through special coding area in its UTR sequence. This leads to reduced activation of both IFNB1 and IFN-related gene ISG15, NFjB, IL-6, and TNF-a induced above. This inhibits immune response mediated by CD147. 374 This inhibition is also mediated by CsA as it blocks CyPA function and subsequently its interaction with CD147. 374 Many viruses successfully replicate by inducing oxidative stress, [376] [377] [378] while CypA is important to mediate their replication. 220,229, 379 Xiao et al.'s study 372 demonstrated that CMV infection induces a substantial level of oxidative stress. 380 This oxidative stress stimulates CyPA production. CyPA plays a role in activating the p38/MAPK pathway. The P38/MAPK pathway is necessary to activate the NFjB transcription factor Elk-1, Sap-1, ATF-2, CREB, CHOP, and Max, [381] [382] [383] [384] [385] [386] mediating viral and cellular gene expression to enhance the virus replication. [387] [388] [389] [390] Silencing of CyPA inhibits virus gene expression. 372 CsA can affect IE1 expression and CyPA activity but not CyPA expression. 372 CsA as CyPA target drug inhibited the CyPA-mediated P38/ MAPK pathway. Additionally, the antioxidant compound can also control and limit virus replication. 372 The ability of CyPA to mediate inflammatory response was reported by van de Berg et al. 380 CMV can also mediate the inflammatory response through CyPA. 372 CMV stimulates CyPA that mediates the activation of both the p38/MAPK and ER1/2 pathways. This mediates the viral replication 372,374 through the expression of IE1 and IE2. 391 HCMV, through its UL4 promoter, activates both p38/MAPK and MAPK/ERK pathways. 392 In addition, both IE1 and IE2 proteins of CMV mediate the viral gene expression 387,393-395 as well as the stimulation of cellular expression factors such as Tef-1, Sp1, c-Jun, JunB, ATF-2, CREB, histone acetyltransferase CREB-binding protein (CBP)associated factor (P/CAF), and p53. 322, [396] [397] [398] [399] Both IE1 and IE2 also play a role in controlling gene activation factor to mediate viral replication and its response to CsA as an antiviral drug.

Cyclosporin A as an immunosuppressive and anti-CMV drug IE2 resembles the most abundant IE proteins that mediate virus gene expression and reproduction. The ability of IE2 to overcome CsA inhibition by CyPA can stimulate viral gene expressions. In addition, both chemokine-like receptor proteins, US3 and US6, interact with HL-AC and HL-AG and affect the expression of MHC class 1 antigen (Figure 4 ), 400,401 enabling viruses to evade the immune response. 402 CMV gene expressions occur in sequence, with the expression of early (E) genes occurring first, followed by IE genes. The IE2 expression will eventually decline, allowing for the inhibition of CyPA by CsA through the formation of the CsA-CyPA complex. This complex inhibits NF-jB, and thus virus transcription. 403, 404 Since the early (E) gene expression will also cascade, no late (L) gene encoding structural protein will be expressed. This leads to the blockage of virus replication and production of virus progeny. Therefore, CsA may be activated by CMV replication 405 while functioning as an antiviral drug by inhibiting virus replication.

CyPA is vital for HCMV lytic infection, latency establishment, and reactivation. This protein can serve as a target in the treatment of HCMV infection. The current review describes the anti-CMV activity of CsA, an immunosuppressive drug commonly used in organ transplantations. However, this drug is associated with HCMV reactivation and toxicities. The immunosuppressive activity of the drug is achieved through the formation of the CsA-CyPA complex that suppresses organ rejection by inhibiting the calcium/calmodulindependent and calcinerin. 353 The IE2 protein is the major IE protein, encoded by the CMV IE gene UL122, which mediates the CMV lytic cycle. 394 IE2 expression depends on which proteins or cellular signals it interacts with during the cascade of events, is core to the determination of whether CsA activates or suppresses virus proliferation. Since viral infections induce expression of inflammatory cytokines 380, 406, 407 and thrive under immunosuppression, the inhibitory effect of CsA is most effective in early stages of the viral replication cycle, when the immune and inflammatory responses are still limited. This review with previously published data shows that CsA has anti-CMV activity. 360, 361 The use of CsA in combination with other drugs approved for the treatment of CMV infections may also prevent the development of unwanted toxicities and drug resistance. 

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

This article does not contain any studies with human participants or animals performed by any of the authors. 

Viral dark matter and virus-host interactions resolved from publicly available microbial genomes

Response of host inflammasomes to viral infection

Progress in the development of new therapies for herpesvirus infections

Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance

DNA polymerase inhibitors for treating hepatitis B: a safety evaluation

Herpesvirus DNA polymerases: structures, functions and inhibitors

Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients

Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel

A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action

Antiretroviral drugs

Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies

UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

Cytomegalovirus replication steps and the actions of antiviral drugs

Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis

Systems biology and the host response to viral infection

Targeting a metabolic pathway to fight the flu

Cellular protein GLTSCR2: a valuable target for the development of broad-spectrum antivirals

Curing a viral infection by targeting the host: the example of cyclophilin inhibitors

Dual role of natural killer cells on graft rejection and control of cytomegalovirus infection in renal transplantation

CMV driven CD8þ T-cell activation is associated with acute rejection in lung transplantation

Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in DþRþ liver transplant patients

Immunosuppressive drugs: the first 50 years and a glance forward

Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection

Impact of early cytomegalovirus infection and disease on longterm recipient and kidney graft survival

Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus

Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression

Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan

Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan

Role of mizoribine in renal transplantation

The antiviral activities of artemisinin and artesunate

The broadspectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-jB) pathway by targeting RelA/p65

Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials

Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study

Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation

The effect of sirolimusbased immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients

Fields virology

Characterization of a novel rat cytomegalovirus (RCMV) infecting placenta-uterus of Rattus rattus diardii

Pathogenesis and vertical transmission of a transplacental rat cytomegalovirus

Murine cytomegalovirus infection in the spleen and its relationship to immunosuppression

RCMV ALL-03 model and study of CMV pathogenesis in congenital infection

Complete genome sequence of rat cytomegalovirus strain ALL-03 (Malaysian Strain)

Identification and comparison of RCMV ALL 03 open reading frame (ORF) among several different strains of cytomegalovirus worldwide

Prevention of cytomegalovirus disease in recipients of solid-organ transplants

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

New estimates of CMV Seroprevalence in Malaysia. Where do we go from here?

Latency and reactivation of human cytomegalovirus

Human cytomegalovirus latency and reactivation in and beyond the myeloid lineage

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

The 'indirect' effects of cytomegalovirus infection

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation

Cytomegalovirus in solid organ transplant recipients

Cytomegalovirus risk factors in renal transplantation with modern immunosuppression

Cytomegalovirus retinitis outcomes in HIV-infected and non-HIV patients at a tertiary care center

Strategies for managing cytomegalovirus in transplant recipients

Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis

Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation

Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection

Congenital cytomegalovirus infection is associated with high maternal socio-economic status and corresponding low maternal cytomegalovirus seropositivity

Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort

Diagnosis of and screening for cytomegalovirus infection in pregnant women

Prediction of maternal cytomegalovirus serostatus in early pregnancy: a retrospective analysis in Western Europe

The "silent" global burden of congenital cytomegalovirus

Management of pregnancies with confirmed cytomegalovirus fetal infection

Neonatal-perinatal medicine

Congenital cytomegalovirus infections

Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging

Hearing outcome of infants with congenital cytomegalovirus and hearing impairment

Congenital cytomegalovirus infection

Cytomegalovirus infection of extremely lowbirth weight infants via breast milk

Congenital and perinatal cytomegalovirus infection

Congenital cytomegalovirus (CMV) infection and hearing deficit

Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention

Physical and intellectual development in children with asymptomatic congenital cytomegalovirus infection: a longitudinal cohort study in Qinba mountain area

Congenital cytomegalovirus infection causing severe inclusion diseases in infants

Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system

Valganciclovir for symptomatic congenital cytomegalovirus disease

Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects

Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection

Congenital cytomegalovirus infection: new prospects for prevention and therapy

Congenital cytomegalovirus infection: audiologic outcome

Establishment of rat brain endothelial cells susceptible to rat cytomegalovirus ALL-03 infection

Brain cell type specificity and gliosis-induced activation of the human cytomegalovirus immediate-early promoter in transgenic mice

Human cytomegalovirus persistently infects aortic endothelial cells

Cultured human brain capillary endothelial cells are permissive for infection by human cytomegalovirus

Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-beta release

Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain

Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV

Pathogenesis of migration disorders

Congenital citomegalovirus infection: a retrospective diagnosis in a child with pachygyria

Magnetic resonance imaging of the brain in congenital rubella virus and cytomegalovirus infections

Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection

Isolation and amino acid sequence of cyclophilin

Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions

The cyclophilins

Structures of immunophilins and their ligand complexes

Cellular functions of immunophilins

Immunophilins: for the love of proteins

Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins

Cyclophilin D as a drug target

Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases

Functional aspects of extracellular cyclophilins

Cyclophilin: a specific cytosolic binding protein for cyclosporin A

Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes

Preferential chemotaxis of activated human CD4þ T cells by extracellular cyclophilin A

Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages

Cyclophilin A: potential functions and therapeutic target for human cancer

Cyclophilin A is required for M-CSF-dependent macrophage proliferation

Cyclophilin A: promising new target in cardiovascular therapy

Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms

Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis

Extracellular cyclophilin A may be a potential target to protect against myocardial reperfusion injury

Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes

EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation

Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice

A search for cyclophilin-A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction

Active site residues of cyclophilin A are crucial for its signaling activity via CD147

Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex

Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction

A novel and functional interaction between cyclophilin A and prolactin receptor

Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A

Cyclophilin A regulates TCR signal strength in CD4þ T cells via a proline-directed conformational switch in Itk

A case study of proline isomerization in cell signaling

Distribution of the cyclosporine binding protein cyclophilin in human tissues

Housekeeping gene expression during fetal brain development in the ratvalidation by semi-quantitative RT-PCR

Cyclophilin A is required for retinoic acid-induced neuronal differentiation in p19 cells

Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells

Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury

Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown

Acutely increased cyclophilin A expression after brain injury: a role in blood-brain barrier function and tissue preservation

Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes

Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c

Melle4] cyclosporin, a novel natural cyclosporin with anti-HIV activity: structural elucidation, biosynthesis and biological properties

Cyclosporine: a revolution in transplantation

Cyclosporine in transplantation -a history of converging timelines

Cyclosporine: a review

Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?

The optimal use of cyclosporin A in autoimmune diseases

Cyclosporin treatment in psoriatic arthritis: a cause of severe leg pain

Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches

Experience with cyclosporine in endogenous uveitis posterior

Cyclosporine A for severe atopic dermatitis in children. Efficacy and safety in a retrospective study of 63 patients

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

Molecular actions of calcineurin inhibitors

T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A

Calcineurin is essential in cyclosporin A-and FK506-sensitive yeast strains

Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast

The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes

AP-1 transcriptional activity requires both T-cell receptor-mediated and costimulatory signals in primary T lymphocytes

Cyclophilin A (CypA) interacts with NF-jB subunit, p65/RelA, and contributes to NF-jB activation signaling

FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal

JNK is involved in signal integration during costimulation of T lymphocytes

Contingent genetic regulatory events in T lymphocyte activation

Transcriptional regulation by calcium, calcineurin, and NFAT

Indirect assessment of renal dysfunction in patients taking cyclosporin A for autoimmune diseases

Cyclosporininduced hypertension: incidence, pathogenesis and management

A transformed view of cyclosporine

The regulation of AP-1 activity by mitogenactivated protein kinases

Diversity in function and regulation of MAP kinase pathways

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signalregulated kinase activation

The MAP kinase cascade is essential for diverse signal transduction pathways

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast

Mitogen-activated protein kinase cascades and regulation of gene expression

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

Cell stress and MEKK1-mediated c-Jun activation modulate NFjB activity and cell viability

AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?

c-Jun-N-terminal kinase signaling is involved in cyclosporine-induced epithelial phenotypic changes

Suppression of NF-jB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response

Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation

Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR zeta/CD3 induction of interleukin-2

p95vav associates with tyrosine-phosphorylated SLP-76 in antigenstimulated T cells

FK506 protects against various immune responses and secondary degeneration following cerebral ischemia

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

Targeting signaling pathways with small molecules to treat autoimmune disorders

PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes

Dual level of interactions between calcineurin and PKC-epsilon in cardiomyocyte stretch

Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes

Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions

Synthesis of cyclosporine and analogues: structural requirements for immunosuppressive activity

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025

Interferon (IFN)-free alisporivir (DEB025) treatment in the VITAL-1 study has a more beneficial overall safety profile vs IFN containing treatment

NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon

SCY-635, a novel nonimmunosuppressive analog of cyclosporine (NTCP)

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

P1044 NVP018, a cyclophilin inhibitor for treatment of chronic HBV infection

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

Cellular proteins in influenza virus particles

In vitro anti-influenza viral activities of constituents from Caesalpinia sappan

Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein

Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle

Cyclosporin A is a differential inhibitor of eukaryotic RNA polymerases

Ultrastructure and morphogenesis of human immunodeficiency virus

Uncoating of HIV-1 requires cellular activation

Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication

Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1

Evolution of the antiretroviral restriction factor TRIMCyp in old world primates

Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp

Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1

A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog

Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B

Specific incorporation of cyclophilin A into HIV-1 virions

Functional association of cyclophilin A with HIV-1 virions

Human cellular restriction factors that target HIV-1 replication

Cyclophilin A levels dictate infection efficiency of human immunodeficiency virus type 1 capsid escape mutants A92E and G94D

Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A

HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency

The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating

A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid

Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop

Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A

Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity

Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A

The nucleoprotein is required for efficient coronavirus genome replication

Nucleocapsid protein expression facilitates coronavirus replication

Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication

Plateletderived growth factor-a receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer

The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry

HCMV requires EGFR signaling to enter and initiate the early steps in the establishment of latency in CD34þ human progenitor cells

Cell signaling by receptor tyrosine kinases

Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus

Human cytomegalovirus induces an atypical activation of Akt to stimulate the survival of short-lived monocytes

Human cytomegalovirus stimulates the synthesis of select Aktdependent antiapoptotic proteins during viral entry to promote survival of infected monocytes

Human cytomegalovirus pUL37x1 induces the release of endoplasmic reticulum calcium stores

HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication

Human cytomegalovirus pUL37x1-induced calcium flux activates PKCa, inducing altered cell shape and accumulation of cytoplasmic vesicles

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

The role of RhoA, RhoB and RhoC GTPases in Cell morphology, proliferation and migration in human cytomegalovirus (HCMV) infected glioblastoma cells

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling

Human kinome profiling identifies a requirement for AMPactivated protein kinase during human cytomegalovirus infection

Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38

Human cytomegalovirus IE 1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element

Murine cytomegalovirus virion-associated protein M45 mediates rapid NF-jB activation after infection

NF-kappaB, CRE and YY1 elements are key functional regulators of CMV promoter-driven transient gene expression in CHO cells

Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters

Binding of SP1 to the immediateearly protein-responsive element of the human cytomegalovirus DNA polymerase promoter

Activation of the interferon response by human cytomegalovirus occurs via cytoplasmic double-stranded DNA but not glycoprotein B

Human cytomegalovirus inhibits apoptosis by regulating the activating transcription factor 5 signaling pathway in human malignant glioma cells

The transcription factor YY1 binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in nonpermissive cells

Cell-specific activity of the modulator region in the human cytomegalovirus major immediate-early gene

Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells

The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients

Three MDBP sites in the immediate-early enhancer-promoter region of human cytomegalovirus

Regulation of the transcription and replication cycle of human cytomegalovirus is insensitive to genetic elimination of the cognate NF-kappaB binding sites in the enhancer

Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?

Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells

Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation

Human cytomegalovirus IE86 attenuates virus-and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression

Control of human cytomegalovirus gene expression by differential histone modifications during lytic and latent infection of a monocytic cell line

Coding potential of laboratory and clinical strains of human cytomegalovirus

Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection

Control of cytomegalovirus lytic gene expression by histone acetylation

Inhibition of the FACT complex reduces transcription from the human cytomegalovirus major immediate early promoter in models of lytic and latent replication

Cytomegaloviruses and their replication

Cell cycle regulation during viral infection

Cell cycle-independent expression of immediate-early gene 3 results in G1 and G2 arrest in murine cytomegalovirusinfected cells

Human cytomegalovirus tegument protein pp150 acts as a cyclin A2-CDK-dependent sensor of the host cell cycle and differentiation state

Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein

Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences

Manipulation of the cell cycle by human cytomegalovirus

Tegument proteins of human cytomegalovirus

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

Tandem E2F binding sites in the promoter of the p107 cell cycle regulator control p107 expression and its cellular functions

Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B

Cyclin-dependent kinase-like function is shared by the beta-and gamma-subset of the conserved herpesvirus protein kinases

Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination

Human cytomegalovirus pUL29/28 and pUL38 repression of p53-regulated p21CIP1 and caspase 1 promoters during infection

Potential role of human cytomegalovirus and p53 interaction in coronary restenosis

The human cytomegalovirus IE2 86 kDa protein elevates p53 levels and transactivates the p53 promoter in human fibroblasts

Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3'-OH kinase pathway and the cellular kinase Akt

PI3K-Akt signaling and viral infection

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2

Inhibition of human cytomegalovirus immediate-early gene expression by cyclin A2-dependent kinase activity

Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle

Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production

The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist

The role of chemokines in neutrophil biology

Human cytomegalovirus gene UL76 induces IL-8 expression through activation of the DNA damage response

Molecular cloning, functional expression, and signaling characteristics of a CC chemokine receptor

US28, a virally-encoded GPCR as an antiviral target for human cytomegalovirus infection

Human cytomegalovirus US28: a functionally selective chemokine binding receptor

Human cytomegalovirus encodes three G protein-coupled receptor homologues

Human cytomegalovirus US28 is important for latent infection of hematopoietic progenitor cells

Leukocyte depletion and infection by cytomegalovirus

Activation of intracellular signaling pathways by the murine cytomegalovirus G protein-coupled receptor M33 occurs via PLC-{beta}/PKC-dependent and -independent mechanisms

Modulation of cellular signaling by herpesvirus-encoded G proteincoupled receptors

The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration

Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs

Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production

Multifaceted evasion of the interferon response by cytomegalovirus

Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway

Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction

Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells

Abrogation of the interferon response promotes more efficient human cytomegalovirus replication

Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog

Human cytomegalovirus microRNAs miR-US5-1 and miR-UL112-3p block proinflammatory cytokine production in response to NF-jB-activating factors through Direct downregulation of IKKa and IKKb

Human cytomegalovirus blocks tumor necrosis factor alpha-and interleukin-1b-mediated NF-jB signaling

Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia

High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia

Cyclophilin A is a proinflammatory cytokine that activates endothelial cells

Recruitment of calcineurin to the TCR positively regulates T cell activation

Ca2þ-induced p38/SAPK signalling inhibited by the immunosuppressant cyclosporin A in human peripheral blood mononuclear cells

CMV promoter is repressed by p53 and activated by JNK pathway

Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells

Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation

Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases

Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2

Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells

Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B

Interferon successfully inhibited refractory cytomegalovirus infection and resulted in CD4þ T-cells increase in a patient with AIDS

Effect of human exogenous leukocyte interferon in cytomegalovirus infections

Human cytomegalovirus immediate-early 2 gene expression blocks virusinduced beta interferon production

The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily

Extracellular cyclophilins contribute to the regulation of inflammatory responses

Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners

Inhibition of cyclophilin A suppresses H2O2-enhanced replication of HCMV through the p38 MAPK signaling pathway

Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl cistrans isomerase activity: direct binding between CyPA and the ectodomain of CD147

Human cytomegalovirus encoded miR-US25-1-5p attenuates CD147/ EMMPRIN-mediated early antiviral response

Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term deficit of adaptive antiviral immunity

Inhibition of influenza infection by glutathione

Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus

Oxidative stress and hepatitis C virus

Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS

Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature

p38 MAPK signalling cascades: ancient roles and new functions

The p38 and ERK MAP kinase pathways cooperate to activate ternary complex factors and c-fos transcription in response to UV light

Stressinduced stimulation of early growth response gene-1 by p38/stress-activated protein kinase 2 is mediated by a cAMP-responsive promoter element in a MAPKAP kinase 2-independent manner

Integration of MAP kinase signal transduction pathways at the serum response element

Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors

Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human

Regulation of human cytomegalovirus gene expression

Phosphorylation of the human cytomegalovirus 86-kilodalton immediate-early protein IE2

The role of MKK1/2 kinase activity in human cytomegalovirus infection

Extracellular signalregulated kinase activity is sustained early during human cytomegalovirus infection

New cell-signaling pathways for controlling cytomegalovirus replication

Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element

The use of recombinant baculoviruses for sustained expression of human cytomegalovirus immediate early proteins in fibroblasts

Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes

Activation and regulation of human cytomegalovirus early genes

The human cytomegalovirus 86-kilodalton major immediateearly protein interacts physically and functionally with histone acetyltransferase P/CAF

Functional interaction between the human cytomegalovirus 86-kilodalton IE2 protein and the cellular transcription factor CREB

Transcriptional activation by the human cytomegalovirus immediate-early proteins: requirements for simple promoter structures and interactions with multiple components of the transcription complex

The human cytomegalovirus IE2 86-kilodalton protein interacts with an early gene promoter via site-specific DNA binding and protein-protein associations

Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2

Dissection of the interaction of the human cytomegalovirus-derived US2 protein with major histocompatibility complex class I molecules: prominent role of a single arginine residue in human leukocyte antigen-A2

Controlling cytomegalovirus: helping the immune system take the lead

Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation

Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-jB

Cytomegalovirus infection in a cyclosporine-treated burn patient: case report

The immune response to human CMV

Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease

The authors would like to express their gratitude to PerkinElmer Inc (PKI) Company to support free version ChemDraw professional 17.1